Breaking News Instant updates and real-time market news.

AERI

Aerie Pharmaceuticals

$26.72

0.03 (0.11%)

05:30
07/05/19
07/05
05:30
07/05/19
05:30

Aerie Pharmaceuticals 2019 guidance 'likely at risk,' says Piper Jaffray

Piper Jaffray analyst Joseph Catanzaro lowered his Q2 estimates for Aerie Pharmaceuticals with a "near complete picture" of Rhopressa and Rocklatan scripts in the quarter. The analyst now models total glaucoma revenue of $15.4M versus the consensus estimate of $18.5M. Street numbers likely need to come down further and Aerie's fiscal 2019 guidance of $110M-$120M will need to be revised, Catanzaro tells investors in a research note. The analyst, who remains "hopeful for an inflection" in the second half of 2019, expects to reassess his numbers post Aerie's Q2 results. Despite the trajectory of script growth, however, doctor checks continue to elicit positive feedback on both Rhopressa and Rocklatan, says Catanzaro. As such, he keeps an Overweight rating on Aerie Pharmaceuticals with a $76 price target. Nonetheless, the analyst believes the company's 2019 guidance is "likely at risk."

  • 10

    Jul

  • 11

    Jul

  • 31

    Jul

  • 01

    Aug

  • 13

    Aug

  • 17

    Sep

AERI Aerie Pharmaceuticals
$26.72

0.03 (0.11%)

06/11/19
ADAM
06/11/19
NO CHANGE
Target $56
ADAM
Buy
Aerie Pharmaceuticals Q2 script numbers too high, says Canaccord
Canaccord analyst Dewey Steadman said Aerie Pharmaceuticals' Rhopressa and Rocklatan prescriptions were likely impacted by the Memorial Day holiday. As a result, the analyst does not believe the prescription run rate can meet his/consensus revenue expectations for the quarter and that estimates will likely need to come down ahead of its Q2 results. Steadman maintained his Buy rating and $56 price target on Aerie Pharmaceuticals shares.
06/11/19
CANT
06/11/19
NO CHANGE
Target $85
CANT
Overweight
Aerie drugs transforming glaucoma treatment space, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros says that with a year's worth of scripts reported for Rhopressa and an early first month look at the Rocklatan launch, he remains confident that Aerie Pharmaceuticals' two drugs are transforming the glaucoma treatment space. With "superior efficacy established" over the number-one prescribed prostaglandin, Aerie's portfolio of glaucoma treatments is best in class, Piros tells investors in a research note. He reiterates an Overweight rating on the shares with an $85 price target.
06/25/19
STFL
06/25/19
NO CHANGE
STFL
Evolus can benefit from 'distraction' at Allergan, says Stifel
After AbbVie (ABBV) announced its intention to acquire Allergan (AGN), Stifel analyst Annabel Samimy said the former clearly sees the latter's Medical Aesthetics business "as a premier, durable, cash-pay franchise and a leader in its field." However, she noted that AbbVie committed to keeping it as a separate business under the Allergan name, which leads Samimy to believe that a spinoff of aesthetics remains a possibility. She also said she would expect "meaningful distraction" at Allergan, "as typical in the midst of an acquisition," which can benefit competitor Evolus (EOLS) as it launches Jeuveau. Samimy, who concluded that she sees today's news potentially bringing interest back to the "washed out" biopharma group, names Revance (RVNC), Aerie Pharmaceuticals (AERI), TherapeuticsMD (TXMD) and Kala Pharmaceuticals (KALA) as being among the potentially attractive targets.
07/02/19
JMPS
07/02/19
NO CHANGE
Target $58
JMPS
Outperform
Aerie Pharmaceuticals price target lowered to $58 from $75 at JMP Securities
JMP Securities analyst Donald Ellis lowered his price target for Aerie Pharmaceuticals to $58 from $75 while reiterating an Outperform rating on the shares. Rhopressa and Rocklatan's scripts are experiencing "impressive growth," but a lower-than forecast average selling price warranted reduced fiscal 2020 estimates, Ellis tells investors in a research note. The analyst says that while Rhopressa's Medicare Part D uptake has been slower than expected, he expects to see an uptick in September and beyond, as patients reach deductibles and typical summer seasonality is in the past.

TODAY'S FREE FLY STORIES

UAL

United Continental

$94.00

2.7 (2.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Earnings
United Continental reports Q2 adjusted EPS $4.21, consensus $4.08 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

VNDA

Vanda Pharmaceuticals

$13.45

-0.13 (-0.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
Vanda Pharmaceuticals announces study results for tradipitant »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

, UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Recommendations
Neuronetics, UnitedHealth analyst commentary  »

UnitedHealth coverage…

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
Cintas sees FY20 EPS $8.30-$8.45, consensus $8.32 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

UAL

United Continental

$94.00

2.7 (2.96%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
United Continental raises FY19 adj. EPS view to $10.50-$12.00, consensus $11.33 »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Earnings
Cintas reports Q4 EPS ex-items $2.07, consensus $1.93 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

CSX

CSX

$79.57

1.05 (1.34%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
CSX says merchandise growth 'offset' intermodal weakness »

Chemicals increased as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PETX

Aratana Therapeutics

$4.94

-0.11 (-2.18%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
Aratana Therapeutics shareholders vote to adopt merger with Elanco Animal Health »

Aratana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$94.00

2.7 (2.96%)

16:15
07/16/19
07/16
16:15
07/16/19
16:15
Earnings
United Continental reports Q2 adjusted EPS $4.21, consensus $4.08 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

KSFTF

Kingsoft

$0.00

(0.00%)

16:15
07/16/19
07/16
16:15
07/16/19
16:15
Downgrade
Kingsoft rating change  »

Kingsoft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.68

1.16 (1.48%)

16:13
07/16/19
07/16
16:13
07/16/19
16:13
Hot Stocks
CSX reports Q2 operating ratio fell to 57.4% since Q2 last year »

Last year's Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PDD

Pinduoduo

$20.13

0.77 (3.98%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Downgrade
Pinduoduo rating change  »

Pinduoduo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCBS

Nicolet Bankshares

$62.76

0.13 (0.21%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Earnings
Nicolet Bankshares reports Q1 EPS $1.91 with items, consensus $1.09 »

During Q2, Nicolet sold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$41.65

-1.39 (-3.23%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Downgrade
Weibo rating change  »

Weibo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip

$36.88

-0.47 (-1.26%)

16:12
07/16/19
07/16
16:12
07/16/19
16:12
Upgrade
Ctrip rating change  »

Ctrip upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.67

1.15 (1.46%)

16:11
07/16/19
07/16
16:11
07/16/19
16:11
Hot Stocks
CSX falls 6% after reporting Q2 results below expectations »

CSX shares are trading at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

SENS

Senseonics

$1.68

-0.075 (-4.29%)

16:10
07/16/19
07/16
16:10
07/16/19
16:10
Syndicate
Senseonics announces $80M convertible senior notes offering »

Senseonics Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

GALXF

Galaxy Resources

$0.00

(0.00%)

16:10
07/16/19
07/16
16:10
07/16/19
16:10
Downgrade
Galaxy Resources rating change  »

Galaxy Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$2.99

0.04 (1.36%)

16:09
07/16/19
07/16
16:09
07/16/19
16:09
Hot Stocks
Inovio to reduce annual burn rate by 25% and workforce by 28% »

Inovio Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SENS

Senseonics

$1.68

-0.075 (-4.29%)

16:08
07/16/19
07/16
16:08
07/16/19
16:08
Syndicate
Senseonics announces $25M common stock offering »

Senseonics Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

BYSI

BeyondSpring

$19.16

-0.12 (-0.62%)

16:08
07/16/19
07/16
16:08
07/16/19
16:08
Syndicate
BeyondSpring files to sell common stock, no amount given »

William Blair &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSK

Verisk Analytics

$151.78

-0.48 (-0.32%)

16:07
07/16/19
07/16
16:07
07/16/19
16:07
Hot Stocks
Appriss acquires retail loss prevention solutions from Verisk Analytics »

Appriss announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 12

    Aug

  • 06

    Sep

FTSV

Forty Seven

$10.08

-0.07 (-0.69%)

16:07
07/16/19
07/16
16:07
07/16/19
16:07
Syndicate
Forty Seven announces $75M common stock offering »

Forty Seven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.